Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer With Anne Chiang, MD, PhD, and Henry Park, MD, MPH

Oncology Data Advisor™ · Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer An estimated 236,740 new cases of lung cancer are reported in the United States annually, and 130,180 people die of the disease. Approximately 14% of cases are classified as small cell lung cancer (SCLC). While SCLC is usually treated with systemic therapy with or without radiation, the 5-year relative survival rate is a dismal 7%, indicating a need for continued research ...

Continue reading

The Burden of Myelosuppressive Hematologic Adverse Events in Small Cell Lung Cancer: Jerome Goldschmidt, MD

For patients with extensive-stage small cell lung cancer (SCLC), cytotoxic chemotherapy remains a mainstay of treatment. However, myelosuppressive hematologic adverse events such as anemia, neutropenia, and thrombocytopenia pose a significant challenge to care. In a study recently presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. Jerome Goldschmidt, medical oncologist at Blue Ridge Cancer Care and the ...

Continue reading

Lurbinectedin for Small-Cell Lung Cancer: Luis Paz-Ares, MD

Last month, the FDA granted accelerated approval to lurbinectedin (ZepzelcaTM, Pharma Mar, S.A.) for adults with metastatic small-cell lung cancer experiencing disease progression on or after platinum-based chemotherapy. In this interview, Luis Paz-Ares, MD, principal investigator of the phase 2 basket trial PM1183-B-005-14 (Study B-005; NCT02454972), on which the approval was based, spoke with i3 Health about the approval's significance, notable adverse events with lurbinectedin, and the wealth...

Continue reading

Lurbinectedin Approved: Metastatic Small-Cell Lung Cancer

The FDA has granted accelerated approval to lurbinectedin (ZepzelcaTM, Pharma Mar, S.A.) for adults with metastatic small-cell lung cancer (SCLC) experiencing disease progression on or after platinum-based chemotherapy. The efficacy of lurbinectedin, a selective inhibitor of oncogenic transcription, was investigated in a multinational, single-arm, open-label phase 2 basket trial, PM1183-B-005-14 (Study B-005; NCT02454972), which enrolled adults with SCLC previously treated with only one chemothe...

Continue reading

DNA Damage Repair Inhibitors Fight Small Cell Lung Cancer

Patients with small cell lung cancer (SCLC) often do not respond to immune checkpoint blockade therapy alone. However, researchers at the University of Texas MD Anderson Cancer Center now report that a combination of immune checkpoint blockade therapy and targeted therapies blocking DNA damage repair significantly shrinks tumors in mouse models of SCLC. "While the use of immunotherapy has revolutionized the way we treat lung cancer, we find that small cell lung cancers can escape the immune syst...

Continue reading

First-Line Atezolizumab Approved: Extensive-Stage SCLC

​The FDA has approved atezolizumab (Tecentriq®, Genentech, Inc.) in combination with carboplatin and etoposide as first-line treatment for patients with extensive-stage (ES) small cell lung cancer (SCLC). This is the first immunotherapy-based combination to be approved in the initial treatment of ES-SCLC. Extensive-stage SCLC has spread widely throughout the lung, to the other lung, to lymph nodes on the other side of the chest, to the fluid around the lung, or to other areas in the body, such a...

Continue reading

Pembrolizumab Approved in Metastatic Small Cell Lung Cancer

Pembrolizumab (Keytruda®, Merck) has received accelerated FDA approval for patients with metastatic small cell lung cancer (SCLC) experiencing disease progression during or after platinum-based chemotherapy following at least one other previous line of therapy. Metastatic SCLC, or extensive-stage SCLC, comprises around 15% of all lung cancers and occurs primarily in heavy smokers. It carries a dismal outlook; only 5% of patients with extensive-stage SCLC live for two years after diagnosis. Appro...

Continue reading

Extensive-Stage SCLC: Adding Durvalumab to Platinum/Etoposide Improves Survival

The phase 3 CASPIAN trial reports that adding durvalumab (Imfinzi®, AstraZeneca) to etoposide and a platinum therapy improves overall survival in patients with extensive-stage small-cell lung cancer (ES-SCLC). Many patients with small-cell lung cancer do not receive a diagnosis until after their disease has already reached the extensive stage, at which point the prognosis is poor. Because immunotherapy has shown some activity in ES-SCLC, the researchers of the CASPIAN trial assessed the efficacy...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.